SMi proudly present the 10th annual Asthma and COPD conference taking place in Central London on Wednesday 2nd and Thursday 3rd April, 2014.
Due to the world's increasingly aging population and rising pollution levels, the global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is set to reach $47bn in 2017.
There is a growing demand for the next generation of inhaled combination products and novel therapeutics. This conference will enable delegates to gain valuable insight into the latest ground-breaking advances in the respiratory drug market. It will focus on the challenges and strategies to enhance patient outcomes, providing extensive knowledge from the key leading industry and academic experts.
The agenda will showcase the treatment for exacerbations, clinical trial design and strategies for method enhancement, biomarkers and the utilization of devices for Asthma and COPD. Key focus will be put on the anti-inflammatory developments in addition to the efficacy and toxicological issues relating to combination products.
Insight will be given on the current regulatory requirements and enable delegates to stay up to date with the guidelines. BUSINESS BENEFITS FOR 2014:
• NEW FOR 2014 - Four round table discussions to enhance networking capabilities between delegates and sponsors
• Hear the latest regulatory advice from the MHRA on new inhaled drugs
• Evaluate strategies to enhance clinical trial design with key talks from Teva and AstraZeneca
• Listen to case studies from University College London and Theravance Inc. on the late stage developments of combination therapies
• Gain insight on U-BIOPRED from committee members, Novartis, the British Lung Foundation and the National Heart & Lung Institute CHAIRMEN FOR 2014:
Noel Snell, Director of Research, British Lung Foundation
Jorgen Vestbo, Professor of Respiratory Medicine, University of Southern Denmark KEY SPEAKERS INCLUDE:
Christine Ward, Principal Scientist, Translational Medicine-RIA, MedImmune
Paul Whittaker, Director/Unit Head for Pre-Clinical Biomarkers Respiratory Disease Area, Novartis
Dr Nithyanandan Nagercoil, Senior Medical Assessor, MHRA
Fan Chung, Professor of Respiratory Medicine and Head of Experimental Studies Medicine, National Heart & Lung Institute
Matthew Catley, Team Leader RIA, AstraZeneca
The 10th annual event is now well known and established within the industry.
Comments from previous installments include: “Excellent, both days” – Prosonix, “Good Networking opportunities” – Novartis
Asthma and COPD 2014 will focus on the cutting edge concepts driving the developments of asthma and COPD forward. This truly is a must attend for respiratory professional.
For further information and to secure your place, click on the event website link.
Alternatively contact Fateja Begum on +44 (0)20 7827 6184 or email email@example.com